ALKEM

The revenue for the quarter ending June 2025 was Rs 3,371.14 Crore, compared to Rs 3,143.75 Crore for the quarter ending March 2025, marking an increase. The net profit for the same period was Rs 668.32 Crore, up from Rs 323.01 Crore in the previous ***** annual revenue for the year ending March 2025 was Rs 12,964.52 Crore, an increase from Rs 12,667.58 Crore in the previous year. Net profit also increased to Rs 2,216.00 Crore from Rs 1,811.46 Crore over the same period. The Debt to Equity ratio has decreased from 0.12 in 2024 to 0.09 in ***** company’s sales increased from Rs 12,667 Crore in March 2024 to Rs 12,964 Crore in March ***** sales for the quarter ending June 2025 increased to Rs 3,371 Crore compared to Rs 3,143 Crore in March 2025. Corporate Actions: August 12, 2025: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome. The audio recording of the Earnings Call for Q1FY26 is available. Alkem Laboratories announced a final dividend of Rs 8 per share (400%) with an effective date of August 8, 2025. Additionally, an interim dividend of Rs 37 per share (1850%) was announced on January 28, 2025, with an effective date of February 14, 2025.